On Monday, Tango Therapeutics Inc (NASDAQ: TNGX) opened lower -4.96% from the last session, before settling in for the closing price of $1.41. Price fluctuations for TNGX have ranged from $1.11 to $12.02 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 103.26%. Company’s average yearly earnings per share was noted -17.02% at the time writing. With a float of $59.12 million, this company’s outstanding shares have now reached $107.73 million.
The extent of productivity of a business whose workforce counts for 155 workers is very important to gauge. In terms of profitability, gross margin is 97.01%, operating margin of -346.08%, and the pretax margin is -309.23%.
Tango Therapeutics Inc (TNGX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Tango Therapeutics Inc is 45.31%, while institutional ownership is 55.97%. The most recent insider transaction that took place on Feb 04 ’25, was worth 8,289. In this transaction General Counsel of this company sold 2,774 shares at a rate of $2.99, taking the stock ownership to the 68,570 shares. Before that another transaction happened on Feb 05 ’25, when Company’s General Counsel sold 2,556 for $3.16, making the entire transaction worth $8,081. This insider now owns 66,014 shares in total.
Tango Therapeutics Inc (TNGX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.35 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -17.02% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.41% during the next five years compared to 7.47% growth over the previous five years of trading.
Tango Therapeutics Inc (NASDAQ: TNGX) Trading Performance Indicators
Check out the current performance indicators for Tango Therapeutics Inc (TNGX). In the past quarter, the stock posted a quick ratio of 6.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.20, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.41 in one year’s time.
Technical Analysis of Tango Therapeutics Inc (TNGX)
The latest stats from [Tango Therapeutics Inc, TNGX] show that its last 5-days average volume of 0.67 million was inferior to 0.78 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 59.17%. Additionally, its Average True Range was 0.18.
During the past 100 days, Tango Therapeutics Inc’s (TNGX) raw stochastic average was set at 7.40%, which indicates a significant decrease from 42.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 116.13% in the past 14 days, which was higher than the 87.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0005, while its 200-day Moving Average is $5.4274. Now, the first resistance to watch is $1.4350. This is followed by the second major resistance level at $1.5300. The third major resistance level sits at $1.6200. If the price goes on to break the first support level at $1.2500, it is likely to go to the next support level at $1.1600. The third support level lies at $1.0650 if the price breaches the second support level.
Tango Therapeutics Inc (NASDAQ: TNGX) Key Stats
There are currently 108,108K shares outstanding in the company with a market cap of 144.87 million. Presently, the company’s annual sales total 42,070 K according to its annual income of -130,300 K. Last quarter, the company’s sales amounted to 4,120 K and its income totaled -37,670 K.
